您的购物车当前为空
别名 比美吉珠单抗, THPTA
Bimekizumab是一种靶向IL17A/IL17F的人源化单克隆抗体,可以降低IL17A/IL17F的水平并阻断炎症驱动的成骨分化,可用于研究银屑病和关节炎。
Bimekizumab是一种靶向IL17A/IL17F的人源化单克隆抗体,可以降低IL17A/IL17F的水平并阻断炎症驱动的成骨分化,可用于研究银屑病和关节炎。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 3,350 | In Stock | |
| 5 mg | ¥ 7,100 | In Stock | |
| 10 mg | ¥ 11,000 | In Stock | |
| 25 mg | ¥ 16,300 | In Stock |
Bimekizumab 相关产品
| 产品描述 | Bimekizumab is a humanised monoclonal antibody targeting IL17A/IL17F, capable of reducing IL17A/IL17F levels and blocking inflammation-driven osteoblast differentiation. It is applicable for investigating psoriasis and arthritis. |
| 体外活性 | 方法:Bimekizumab (10 μg/mL, 1 小时)处理人骨膜细胞(hPDCs),通过实时定量PCR分析成骨相关基因的表达。 |
| 别名 | 比美吉珠单抗, THPTA |
| CAS No. | 1418205-77-2 |
| 颜色 | Transparent |
| 物理性状 | Liquid |
| 存储 | store at low temperature,keep away from direct sunlight | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
评论内容